Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board
“2020 is an important year at Ovid. We anticipate clinical data across both our neurodevelopmental and rare epilepsy programs, including from our pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; our Phase 2 ROCKET signal-finding trial with OV101 in Fragile X syndrome; as well as our open-label Phase 2 ARCADE trial with OV935 in CDKL5 and Dup15Q syndrome; and the double-blind, placebo-controlled Phase 2 ELEKTRA trial with OV935 in Lennox-Gastaux syndrome and Dravet syndrome,” said
“I am very excited to work with the Ovid team and support their efforts in taking a meaningful step forward in the development of treatments for patients with rare neurological diseases,” said
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit http://www.ovidrx.com/.
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding: advancing and commercializing Ovid’s product candidates, progress, timing, scope and the potential therapeutic benefits based on results of clinical trials for Ovid’s product candidates; and the anticipated reporting schedule of clinical data regarding Ovid’s product candidates. You can identify forward-looking statements because they contain words such as “will,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors”. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Investors and Media:
Investor Relations & Public Relations
Source: Ovid Therapeutics Inc.